Trial · NCT03323749
Adverse events316
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 316
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection site erythema | General disorders | Double-Blind Elamipretide | 94 | 109 | |
| other | Injection site erythema | General disorders | Double-Blind Placebo | 31 | 109 | |
| other | Injection site erythema | General disorders | Open-Label Elamipretide | 66 | 93 | |
| other | Injection site erythema | General disorders | Open-Label Placebo | 87 | 103 | |
| other | Injection site pruritus | General disorders | Double-Blind Elamipretide | 82 | 109 | |
| other | Injection site pruritus | General disorders | Double-Blind Placebo | 10 | 109 | |
| other | Injection site pruritus | General disorders | Open-Label Elamipretide | 57 | 93 | |
| other | Injection site pruritus | General disorders | Open-Label Placebo | 81 | 103 | |
| other | Injection site pain | General disorders | Double-Blind Elamipretide | 43 | 109 | |
| other | Injection site pain | General disorders | Double-Blind Placebo | 20 | 109 | |
| other | Injection site pain | General disorders | Open-Label Elamipretide | 32 | 93 | |
| other | Injection site pain | General disorders | Open-Label Placebo | 37 | 103 | |
| other | Injection site swelling | General disorders | Double-Blind Elamipretide | 42 | 109 | |
| other | Injection site swelling | General disorders | Double-Blind Placebo | 7 | 109 | |
| other | Injection site swelling | General disorders | Open-Label Elamipretide | 29 | 93 | |
| other | Injection site swelling | General disorders | Open-Label Placebo | 20 | 103 | |
| other | Injection site induration | General disorders | Double-Blind Elamipretide | 31 | 109 | |
| other | Injection site induration | General disorders | Double-Blind Placebo | 6 | 109 | |
| other | Injection site induration | General disorders | Open-Label Elamipretide | 25 | 93 | |
| other | Injection site induration | General disorders | Open-Label Placebo | 41 | 103 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03323749/events